Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.43 |
| ▸ | MGMT | P16455 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648620 | 0.80 | L3MBTL1 (0.47) | MGMTTLR8L3MBTL1 | |
| SCHEMBL1406446 | 0.78 | SYK (0.65) | SYKAURKBINCENPNOS3NOS1 | |
| SCHEMBL7544748 | 0.77 | MGMT (0.50) | MGMTHTR2AHTR2CHTR2BL3MBTL1 | |
| SCHEMBL6190711 | 0.75 | SYK (0.69) | SYKAURKBINCENPNOS3NOS1 | |
| SCHEMBL5652395 | 0.74 | PIN1 (0.45) | TLR8PARP10HRH4 | |
| SCHEMBL3378270 | 0.72 | TSHR (0.38) | NOS3NOS1NOS2L3MBTL1 | |
| SCHEMBL4235232 | 0.72 | SYK (0.54) | SYKMGMTHTR2AHTR2CHTR2B | |
| SCHEMBL30716906 | 0.72 | SYK (0.54) | SYKMGMTHTR2AHTR2CHTR2B | |
| SCHEMBL5651640 | 0.72 | MAOB (0.49) | MGMT | |
| SCHEMBL20526953 | 0.72 | PARP10 (0.51) | SYKAURKBINCENPPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1147485-C | Indoline derivatives useful as 5-HT-2C receptor antagonists | ʷ��˿�������ȳ�ķ����˾ | 2004-04-28 | — | — | CN | disclosed |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-03-21 | — | — | US | disclosed |
| US-6313145-B1 | FOR THERAPY OF ANXIETY AND/OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-06 | — | — | US | disclosed |
| EP-0912556-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-04 | — | — | EP | disclosed |
| CN-1222152-A | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-07-07 | — | — | CN | disclosed |
| EP-0912556-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048700-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | HTR2C, HTR1A, HTR1D | SYK 1978/4885GABRA1 207/4885GABRG2 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.